Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06568562
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-21
Brief Title:
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
PRO-XL A Phase II Study of XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer After Progression on Lutetium-177 177Lu-PSMA-617
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRO-XL
Brief Summary:
The purpose of this study is to determine how well the study drug XL092 is helping to treat a participants cancer after 16 weeks of treatment Researchers will also look at how safe the XL092 is and how well the XL092 is working XL092 is an oral tablet that will be taken once a day Participants will return to clinic for regular visits for checkups and tests
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None